A phase I study of CLAG regimen [cladribine, cytarabine] in combination with imatinib mesylate (Gleevec) in refractory or relapsed leukemia.
Phase of Trial: Phase I
Latest Information Update: 15 Oct 2013
At a glance
- Drugs Imatinib (Primary) ; Cladribine; Cytarabine
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia
- Focus Adverse reactions
- 22 Jan 2009 Planned patient numbers amended from 12 to 18 as reported by ClinicalTrials.gov.
- 01 Oct 2006 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 13 Jan 2006 New trial record.